Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03833921 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
A Phase 2 study of Prostate Cancer and Prostate Cancer Metastatic, sponsored by Martha Mims.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 3
- Study locations
NCT03833921 is a Phase 2 study of Prostate Cancer and Prostate Cancer Metastatic that is actively recruiting participants, run by Martha Mims. The registered enrollment target is 130 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT03833921, a Phase 2 study of Prostate Cancer and Prostate Cancer Metastatic, is actively recruiting participants, sponsored by Martha Mims.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 3
- Study locations
Study Summary
The investigators are conducting this study with men that have prostate cancer and are getting standard of care treatment with the drugs abiraterone acetate and prednisone. The study will follow men with prostate cancer from initiation of participation in the study and for up to 10 years. The reason for the study is that researchers think that there may be a connection between the race and ethnicity of men with prostate cancer and how well the standard treatments work for the participants.
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Abiraterone Acetate
Study Locations (3)
Texas
- Ben Taub General Hospital - Houston
- Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine - Houston
- Michael E. DeBakey Veterans Affairs Medical Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2019-05-23 |
| Est. Completion | 2038-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03833921
The ClinicalTrials.gov registry entry for NCT03833921 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% lower). The listed sponsor is Martha Mims, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Prednisone is the first listed.
NCT03833921 reports 3 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03833921 about?
NCT03833921 is a clinical study titled "Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer". The investigators are conducting this study with men that have prostate cancer and are getting standard of care treatment with the drugs abiraterone acetate and prednisone. The study will follow men with prostate cancer from initiation of participation in the study and for up to 10 years. The reason...
What is the current status of trial NCT03833921?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2019-05-23. Estimated completion is 2038-04.
What conditions does trial NCT03833921 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostate Cancer Metastatic.
What interventions are being tested in trial NCT03833921?
The interventions under investigation include: Prednisone (DRUG), Abiraterone Acetate (DRUG).
Who is sponsoring clinical trial NCT03833921?
This trial is sponsored by Martha Mims, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03833921 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.